BRIEF-Versus-7375 Demonstrates Clinical Activity With A Favorable Safety And Tolerability Profile In Target-D 101

Verastem, Inc.

VSTM

0.00

June 23 (Reuters) - Verastem Inc VSTM.O:

VERSUS-7375 DEMONSTRATES CLINICAL ACTIVITY WITH A FAVORABLE SAFETY AND TOLERABILITY PROFILE IN TARGET-D 101 PHASE 1/2 CLINICAL TRIAL IN PATIENTS WITH ADVANCED KRAS G12D-MUTATED SOLID TUMORS
VERASTEM - VERSUS-7375 SHOWS ANTI-TUMOR ACTIVITY WITH ANTI-EGFR THERAPY OR STANDARD CHEMOTHERAPY
VERASTEM - VERSUS-7375 SAFETY PROFILE MAINLY LOW-GRADE GI EVENTS THAT DECREASE AFTER CYCLE 1
VERASTEM - CO AND ERASCA ANNOUNCE INTENT TO EVALUATE VERSUS-7375 WITH ERAS-15 IN KRAS G12D TUMORS

Source text: ID:nBwb7BF3fa

Further company coverage: VSTM.O

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.